China’s Shenzhen Hepalink seeks approval for RMB 1 billion of corporate bonds

Chicago, Sept. 30 – Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is proposing a RMB 1 billion issue of corporate bonds in multiple tranches, according to an announcement.

The bonds are aimed at professional investors.

Tenors will be up to five years.

Proceeds will be used to repay debt, adjust the company’s debt structure and replenish the working capital of the company.

Approval for the issuance will be valid for 24 months, once passed by the board and after approval by way of special resolution at an extraordinary general meeting

The company manufactures and distributes pharmaceutical products, including heparin sodium active pharmaceutical ingredients, heparin sodium and enoxaparin sodium.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.